HCP, Inc. (HCP) Stake Decreased by Plimoth Trust Co. LLC

Plimoth Trust Co. LLC reduced its stake in shares of HCP, Inc. (NYSE:HCP) by 2.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,763 shares of the real estate investment trust’s stock after selling 915 shares during the quarter. Plimoth Trust Co. LLC’s holdings in HCP were worth $1,150,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of HCP by 0.3% during the third quarter. Vanguard Group Inc. now owns 75,247,949 shares of the real estate investment trust’s stock valued at $1,980,527,000 after purchasing an additional 196,049 shares during the last quarter. Vanguard Group Inc boosted its stake in HCP by 0.3% in the third quarter. Vanguard Group Inc now owns 75,247,949 shares of the real estate investment trust’s stock valued at $1,980,527,000 after acquiring an additional 196,049 shares during the last quarter. BlackRock Inc. boosted its stake in HCP by 4.1% in the fourth quarter. BlackRock Inc. now owns 46,146,172 shares of the real estate investment trust’s stock valued at $1,288,861,000 after acquiring an additional 1,830,425 shares during the last quarter. Cohen & Steers Inc. boosted its stake in HCP by 35.0% in the fourth quarter. Cohen & Steers Inc. now owns 22,898,362 shares of the real estate investment trust’s stock valued at $639,551,000 after acquiring an additional 5,935,752 shares during the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC boosted its stake in HCP by 73.8% in the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 14,036,864 shares of the real estate investment trust’s stock valued at $392,050,000 after acquiring an additional 5,960,734 shares during the last quarter. 95.64% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:HCP traded up $0.68 during midday trading on Friday, reaching $29.83. 3,567,076 shares of the company were exchanged, compared to its average volume of 3,191,457. HCP, Inc. has a fifty-two week low of $21.80 and a fifty-two week high of $32.23. The company has a quick ratio of 0.64, a current ratio of 0.64 and a debt-to-equity ratio of 0.85. The firm has a market cap of $14.25 billion, a price-to-earnings ratio of 16.39, a PEG ratio of 7.68 and a beta of 0.46.

HCP (NYSE:HCP) last issued its quarterly earnings data on Wednesday, February 13th. The real estate investment trust reported $1.73 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $1.30. HCP had a net margin of 57.41% and a return on equity of 18.40%. The business had revenue of $441.92 million for the quarter, compared to analyst estimates of $445.81 million. During the same period last year, the business posted $0.48 earnings per share. The firm’s quarterly revenue was down .3% on a year-over-year basis. Research analysts expect that HCP, Inc. will post 1.74 earnings per share for the current fiscal year.

HCP has been the topic of a number of recent research reports. Zacks Investment Research raised shares of HCP from a “sell” rating to a “hold” rating in a research note on Thursday, March 14th. BMO Capital Markets reaffirmed a “buy” rating and issued a $33.00 price objective on shares of HCP in a research note on Wednesday, February 13th. Robert W. Baird raised shares of HCP from a “neutral” rating to an “outperform” rating in a research note on Monday, January 7th. TheStreet raised shares of HCP from a “c” rating to a “b-” rating in a research note on Wednesday, February 13th. Finally, Morgan Stanley set a $32.00 price objective on shares of HCP and gave the company a “hold” rating in a research note on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $28.95.

COPYRIGHT VIOLATION NOTICE: “HCP, Inc. (HCP) Stake Decreased by Plimoth Trust Co. LLC” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2019/04/19/hcp-inc-hcp-stake-decreased-by-plimoth-trust-co-llc.html.

HCP Profile

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Read More: Trading Options- What is a Strangle?

Institutional Ownership by Quarter for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.